Back to Search Start Over

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Source :
GlobeNewswire. August 25, 2021
Publication Year :
2021

Abstract

SAN FRANCISCO, Aug 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company's Phase 2 clinical study of roxadustat, a [...]

Subjects

Subjects :
FibroGen Inc. -- Product development
Anemia -- Drug therapy
Biotechnology industry -- Product development
Clinical trials
Banking, finance and accounting industries
Business

Details

Language :
English
Database :
Gale General OneFile
Journal :
GlobeNewswire
Publication Type :
News
Accession number :
edsgcl.673100100

Tools

Authors Abstract Subjects Details